

David T Durack, MB, D Phil, FRCP, FRACP, FACP

BRIEF BIOSKETCH

Dr. David T Durack is Consulting Professor of Medicine at Duke University, and was Senior Vice President, Corporate Medical Affairs and Chief Medical Officer at Becton Dickinson & Co. (retired 10/2012). Education: Correspondence School of West Australia; Scotch College, West Australia; University of West Australia medical degree '69; Rhodes Scholar at Oxford University UK, Doctor of Philosophy '73, doctoral thesis entitled "Experimental Endocarditis". Internship and residency at Radcliffe Infirmary, Oxford and Royal Postgraduate Medical School, Hammersmith Hospital, London. Chief Resident and Faculty member, Department of Medicine, University of Washington, '74-'77. Chief, Division of Infectious Diseases and International Health and Professor of Medicine, Duke University, '77-'94. Research interests: pathogenesis and chemotherapy of Infective Endocarditis and other bacterial, viral and fungal infections. He is a Fellow of the Royal College of Physicians (UK), the Royal Australasian College of Physicians and the American College of Physicians; he has published more than 230 articles and textbook chapters and co-edited several textbooks. Dr. Durack has been elected to the American Society for Clinical Investigation, the Council of the Infectious Diseases Society of America, and the American Academy of Microbiology. He has served on an FDA Review Panel, the Joint Commission Resources Board of Directors, and as Chairman of the Board, ASM Resources. In addition to his clinical and research activities, he has 17 years' experience as a senior executive in the medical devices and diagnostics industry, and currently provides consultation to medical technology companies.

CURRICULUM VITAE

DAVID TULLOCH DURACK

M.B., D. Phil. (Oxon) FRCP, FRACP, FACP

PERSONAL DATA

Born: Perth, Western Australia
Citizenship: United States
Married: Carmen Elizabeth Prosser
Children: Jeremy Charles Durack, MD
Kimberley David Durack, BA
Sonya Elizabeth Durack Maxwell, BA
Justin Rooks Durack, MSc, MBA

CURRENT POSITION

Consulting Professor of Medicine, Duke University
Consultant in Medicine, Biotechnology and Global Health

HOME and HOME OFFICE ADDRESS

1700 Woodstock Road, Durham NC 27705-5232, USA
Telephone +1-919-257-1943 E-mail: durackdt@gmail.com

EDUCATION

1949-1956 Correspondence School of Western Australia
1957-1961 Scotch College, Perth, Western Australia
1962-1968 School of Medicine, University of Western Australia
1969-1973 Oxford University, Oxford, England (Rhodes Scholar)

DEGREES

1969 M.B., B.S. (Honors), University of Western Australia, Perth, WA
1973 Doctor of Philosophy, Oxford University, Oxford, UK

SPECIALTY CERTIFICATION

1973 Royal College of Physicians, FRCP (U.K)
1974 Royal Australasian College of Physicians, FRACP
1975 American Board of Internal Medicine, FACP

LICENSURE TO PRACTICE MEDICINE

1969 Western Australia Registration No. PG-3667 (inactive)
1970 United Kingdom GMC No. 1432697 (inactive)
1974 Washington, U.S.A., No. 0014030 (inactive)

1977 North Carolina, U.S.A., No. 22337 (active)

POSTGRADUATE TRAINING

- Feb 1969 - House Physician, Nuffield Department of Medicine, Radcliffe
July 1969 Infirmary, Oxford, England (Professor Sir Paul B. Beeson).
- Aug 1969 - House Surgeon, Nuffield Department of Surgery, Radcliffe Infirmary,
Jan 1970 Oxford, England (Professor Philip Allison).
- Feb 1970 - Postgraduate student/Doctor of Philosophy, Oxford, England.
Jan 1973 (Thesis Supervisor: Professor Sir Paul B. Beeson.)
- Feb 1973 - Senior House Physician, Nuffield Department of Medicine, Radcliffe
July 1973 Infirmary, Oxford.
- Aug 1973 - Senior House Physician, Department of Medicine, Royal Postgraduate
Jan 1974 Medical School, Hammersmith Hospital, London, U.K. (Professor Sir Christopher Booth).
- July 1974 - Chief Resident in Medicine, University of Washington Hospital,
July 1975 Seattle, WA, U.S.A. (Chief of Service Robert G. Petersdorf, M.D.)

FACULTY AND ADMINISTRATIVE APPOINTMENTS

- 1972 – 1973 Lecturer, Nuffield Department of Clinical Medicine, Oxford, England
- 1974 - 1975 Acting Instructor in Medicine, University of Washington, Seattle, Washington
- 1975 - 1977 Acting Assistant Professor of Medicine, University of Washington, Seattle, Washington
- 1977 - 1982 Associate Professor of Medicine, Duke University Medical Center, Durham, North Carolina
- 1977 - 1983 Associate Professor of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina
- 1977 -1994 Chief, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina
- 1982 -1994 Professor of Medicine with tenure, Duke University Medical Center, Durham, North Carolina
- 1995 - present Consulting Professor of Medicine, Duke University Medical Center
- 1982 - 1983 Acting Chairman, Department of Medicine, Duke University Medical Center, Durham, North Carolina

- 1983 -1994 Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Duke University, Durham, NC
- 1988 - 1989 Visiting Scholar (Sabbatical), Department of Microbiology and Immunology, Stanford University, Palo Alto, CA. (Laboratory of John C Boothroyd, PhD)
- 1989 -1994 Director, Duke University Endocarditis Service
- 1994 -1995 Chairman, Department of Medicine; Chief, Division of Infectious Diseases; Medical Director, Microbiology Laboratory, Health Care International (Scotland) Ltd, Clydebank G81 4HX Scotland United Kingdom
- 1995 - 1998 Worldwide Medical Director, Becton Dickinson Microbiology Systems, Baltimore, MD 21152 USA; 1998 --Vice-President, Medical Affairs
- 1998 - 1999 Vice-President, Medical Affairs, Becton Dickinson Diagnostic Systems, Baltimore, MD 21152-0999 USA
- 1999 - 2005 Vice President, Corporate Medical Affairs and Chief Medical Officer, Becton Dickinson & Company, Franklin Lakes, NJ 07417-1883 USA
- 2006 - 2012 Senior Vice President, Corporate Medical Affairs, Becton Dickinson & Company, Franklin Lakes, NJ 07417-1883 USA

PROFESSIONAL AND ACADEMIC SOCIETIES

- 1977 - Fellow of the American College of Physicians
- 1977 - Fellow of the Royal Australasian College of Physicians
- 1977 - Fellow of the Infectious Diseases Society of America
- 1977 - 2002 American Federation for Medical Research
- 1978 - American Society for Microbiology
- 1978 - 1982 Southern Society for Clinical Investigation
- 1980 - American Rhodes Scholars
- 1981 - Fellow of the Royal College of Physicians (UK)
- 1983 - Alpha Omega Alpha
- 1985 - American Society for Clinical Investigation
- 1997 - Fellow of the American Academy of Microbiology

HONORS

- 1962 Distinctions in all seven subjects in matriculation examination
- 1962 Winthrop Scholar, University of Western Australia
- 1962 General Exhibition and Commonwealth Scholarship
- 1964 Convocation Prize in Medicine, University of Western Australia
- 1965 Georgian's Prize, St George's College (shared)
- 1965 Elsie Louise Simpson Prize in Biochemistry
- 1965 John and Louisa Cowcher Memorial Prize in Anatomy
- 1965 Boots Proprietary Limited Prize in Physiology
- 1966 Marion Margaret Bergin Memorial Prize
- 1966 Royal Perth Hospital Clinical Association Prize in Surgery (shared)
- 1967 Gilbert Troup Prize in Anaesthetics

| | |
|-----------|---|
| 1967 | Carnation Company Prize in Infant and Child Health |
| 1968 | Helen Jane Lamard Prize in Surgery (shared) |
| 1968 | Queen Elizabeth II Coronation Gift Fund Trust Prize (shared) |
| 1968 | John Lindsay Taylor Memorial Prize in Gynaecology |
| 1968 | Rhodes Scholarship, Western Australia |
| 1974 | Lilly International Fellow, Australia |
| 1981 | Eugene A Stead Jr Award for Excellence in Teaching |
| 1981 | Elected Fellow, Royal College of Physicians, UK (FRCP) |
| 1983 | Elected to Alpha Omega Alpha |
| 1985 | Elected to the American Society for Clinical Investigation |
| 1987 | Elected Councillor, Infectious Diseases Society of America |
| 1991 | G E Rennie Memorial Medal, Royal Australasian College of Physicians, presented at Annual Meeting, Perth, Western Australia. |
| 1992/1995 | Listed in <i>"The Best Doctors in America"</i> |
| 1997 | Listed in <i>"The International Who's Who"</i> |
| 2001 | Honorary Life Member, Australasian Society of Infectious Diseases |

SELECTED VISITING PROFESSORSHIPS AND LECTURESHIPS

| | |
|------|---|
| 1978 | Lilly Visiting Professor, Australia |
| 1978 | Plenary Lecturer, World Congress of Cardiology, Tokyo Japan |
| 1982 | Franz J. Ingelfinger Visiting Professor, Boston City Hospital, Boston University |
| 1984 | Harvard Medical School, Beth Israel Deaconess Hospital |
| 1984 | Albert Einstein College of Medicine, Montefiore Hospital |
| 1985 | Roussel Visiting Professor, Australia |
| 1986 | Dascomb Visiting Lectureship, Tulane University |
| 1986 | Visiting Professor, King Faisal Specialist Hospital, Riyadh, Saudi Arabia |
| 1987 | Visiting Professor, 33rd Interns and Residents Day, University of Oklahoma College of Medicine |
| 1987 | Visiting Professor, Royal Postgraduate Medical School, Hammersmith Hospital, London, England |
| 1989 | Brainerd Lecturer, University of California, San Francisco |
| 1989 | Noble Wiley Jones Visiting Professor, University of Oregon Health Sciences Center |
| 1990 | Endocarditis Symposium, XI World Congress of Cardiology, Manila, Philippines |
| 1990 | Royal College of Physicians and Royal College of Pathology Joint Conference on Infectious Diseases, London, England |
| 1991 | P.B. Smith Lectureship Award, Fremantle Hospital, Western Australia |
| 1991 | Invited Speaker, First International Symposium on Modern Concepts in Endocarditis, Munich, Germany |
| 1992 | Invited Speaker, XIX Congreso Argentino de Cardiologia, Buenos Aires, Argentina |
| 1992 | Invited Speaker, American College of Cardiology 41st Scientific Session, Dallas, TX |
| 1992 | Invited Speaker, Research Forum International, Vienna, Austria |
| 1992 | Visiting Professor and Thesis examiner (Dr. Jan van der Meer), Leiden, Holland |
| 1992 | Invited Speaker, Endocarditis Symposium, Freiburg University, Germany |

- 1993 Keynote Speaker, Inaugural Meeting, Hellenic Society of Infectious Diseases, Athens, Greece
- 1993 Glaxo Lecturer, National Taiwan University Hospital, Taipei, Taiwan
- 1993 Keynote Speaker, 40th Anniversary Symposium, Taipei Jen-Ai Hospital, Taiwan
- 1993 Consultant on Health, Tan Thuan Co. EPZ, Saigon (Ho Chi Minh City), Vietnam
- 1993 Scientific Committee Member and Speaker, Second International Symposium on Modern Concepts in Endocarditis, Copenhagen, Denmark
- 1993 Invited Speaker, International Society of Chemotherapy, Stockholm, Sweden
- 1993 Visiting Professorship, Alfred Hospital, Melbourne, Australia
- 1994 Visiting Expert to Ministry of Health, Singapore
- 1994 Invited Lecturer, ISID Congress, Prague, Czech Republic
- 1994 Invited Lecturer, World Congress of Cardiology, Berlin, Germany
- 1994 Joseph E. Geraci Lecturer, Mayo Clinic
- 1994 Invited Lecturer, Western Pacific Congress of Chemotherapy and Infectious Diseases, Manila, Philippines
- 1995 Speaker, Workshop on Collaborative Drug Discovery, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- 1995 Speaker, Endocarditis Symposium, Copenhagen, Denmark
- 1995 Consultant to Ministry of Health, Abu Dhabi, United Arab Emirates
- 1995 Visiting Professor, FUNCEI, Buenos Aires, Argentina
- 1995 Plenary lecturer, Simposio Endocarditis, Montevideo, Uruguay
- 1995 Plenary Lecture, Pan American Congress of Infectious Diseases, Cartagena, Colombia
- 1995 Organizing Committee, 3rd International Symposium on Modern Concepts in Endocarditis, Boston, Massachusetts
- 1996 Symposium Chair, International Society for Infectious Diseases, Hong Kong
- 1996 Lecturer, Chinese Society for Infectious Diseases, PUMC, Beijing, China
- 1996 Plenary Lecture, Colombian Society for Internal Medicine, Bogota, Colombia
- 1997-9 Lecturer and Council member, 4th and 5th International Symposia on Cardiovascular Infections, Switzerland and Holland
- 1999 Historical CPC: The Death of Pericles and the Plague of Athens, University of Maryland Medical System, Baltimore MD
- 1999 Zucker Visiting Professor, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York NY
- 1999 Commencement speaker, University of Utah Medical School, Class of '99
- 2000 Keynote Lecturer, Netherlands Heart Foundation, Boerhaave Cursus, Leiden, Holland
- 2000 Lecturer, Societe Medicale des Hopitaux de Paris, Cent Cinquantenaire, France
- 2001 Sir Macfarlane Burnet Lecture, ASID, Melbourne, Australia
- 2002 Keynote speaker, International Symposium on Endocarditis, Santiago, Chile
- 2009 Opening Speaker, 10th ISCVI Meeting, Naples, Italy
- 2009 Invited speaker, ASM 50th Anniversary Meeting, Perth, West Australia
- 2010 Plenary Lecturer, South American Infectious Diseases Society (SAID), Mar del Plata, Argentina
- 2015 Opening speaker and invited lecturer, 13th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections (ISCVI 2015), Rio de Janeiro, Brazil

2019 Keynote Speaker, Infective Endocarditis Symposium, Prince Charles Hospital,
Brisbane Australia

SPECIAL RESPONSIBILITIES

Consultant to Committee on Rheumatic Fever, American Heart Association, 1976-77
Member of Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, American Heart Association, 1978-94
Member, NIAID Collaborative Antiviral Study Group, 1978-81
Member, Executive Committee of the Council on Cardiovascular Disease in the Young, American Heart Association, 1981-83
Member, Medical Research Service Merit Review Board for Infectious Disease, Veterans Administration, 1981-84
Elected Delegate, Duke University Academic Council, 1983-85; 1990-94
Publications Committee, Infectious Diseases Society of America, 1985-88
Editorial Board, American Journal of Medical Science, 1985--
Editorial Board, Antimicrobial Agents and Chemotherapy, 1989--
Supervisor, Divisional Quality Assurance Committee, 1985-94
Member, AMA Council on Scientific Affairs Panel on AIDS, 1986-88
Member, American College of Physicians MKSAP VIII Committee, 1986-1987
President, Section on Infectious Diseases and Virology, Pan American Medical Association, 1984-1989
Member, AMA Diagnostic and Therapeutic Technology Assessment Panel, 1987-89
Councilor, Infectious Diseases Society of America, 1988-1990
Associate Editor, Oncology, 1989--1996
Chairman, Infectious Diseases Society of America Ethics Committee, 1989-94
International Affairs Committee, Infectious Diseases Society of America, 1990-94
Advisory Panel on International Health, United States Pharmacopeia, 1990-94
Member, American College of Physicians Committee to produce the Medical Knowledge Self-Assessment Program (MKSAP) in the Subspecialty of Infectious Diseases, 1991-94
Duke University Parents' Committee, 1991-94
Advisory Editor, Marcel Dekker Inc., Publishers, 1993-4
NIH/NIAID Study Section: Microbiology and Infectious Diseases Research Committee, 1992-4
Duke/Durham Executive Leadership Board, 1993-94
Duke University Provost's Executive Committee on International Affairs, 1993-94
NIH Blue Ribbon Panel on Tuberculosis, 1994
Board of Trustees, National Foundation for Infectious Diseases, 1996—
WHO Advisory Group on Tuberculosis Research, 1997-2000
American Society for Microbiology President's Task Force on Corporate Relations, 1999-
American Society for Microbiology Task Force on ASM For-Profit activities, 1999-
International Advisory Board, *Clinical Microbiology and Infection*, 1999-2003
Council Member, International Society for Cardiovascular Infectious Diseases, 2000-
FDA Microbiology Devices Advisory Panel, 2000-2004
Global Medical Advisory Board, AmeriCares, 2010-2013

PHARMACEUTICAL INDUSTRY AND BIOTECHNOLOGY ACTIVITIES

Anti-Infective Advisory Council, E.R. Squibb & Sons, Princeton, N.J., 1984-1985
Roche Laboratories Medical Advisory Board, 1988-93

Smith Kline Beecham Hepatitis Advisory Board, 1989-94
Eli Lilly Anti-infectives Advisory Board/Southeastern Group, 1992-94
Independent Board member, PixelEXX Systems, Inc
Chair, Medical and Scientific Advisory Board, Magnolia Medical Technologies Inc

CONSULTANCY ACTIVITIES:

Alkermes, Inc. Boston MA; 1989-92 Areas : Drug delivery systems for treatment of diseases of the central nervous system; crossing the blood-brain barrier

Eukarion Inc. Boston MA; 1990-94 Areas: Drug discovery; antibody therapy; HIV therapy

Cato Research Limited, Research Triangle Park, N.C. 1991-95 Areas: development and pre-clinical and clinical Phase I, II, and III trials for drugs, antivirals, immuno-stimulators and other biologicals.

Protein Engineering Corporation, Boston MA; 1993-95 Areas: Development of proteins as therapeutic agents for infectious diseases

Remicalm Inc., Houston TX; 2013 – Area: Diagnostic devices: product development, clinical development, registration and marketing strategy

Bertech Pharma, Canada; 2013 - Area: Diagnostics and drugs: product development, clinical development, registration and marketing strategy

Magnolia Medical, Seattle WA; 2013 – Chair, Scientific Advisory Board; Area: Medical devices

Dr Durack provides consultation services in the fields of Internal Medicine, Infectious Diseases, Microbiology, and related Biotechnology; also medico-legal expert opinion in the areas of Internal Medicine and Infectious Diseases

RESPONSIBILITIES FOR BECTON DICKINSON: Senior Vice President, Medical Affairs; Member of BD Corporate **Leadership Team**, reporting to the President and CEO; Member of the **Management Committee** (executive subgroup of the Leadership team). In charge of: **Corporate Medical Affairs and Clinical Operations** (18 MDs, 7 PhDs, 185 Clinical Research Associates, nurses, and support staff), with an annual budget of \$55 million; and of **Corporate Pre-Clinical Development and Toxicology** (4 PhDs and 21 technical staff), with an annual budget of \$4.5 million. Overall responsibility for Clinical Trials for all BD devices and diagnostics in development, with special emphasis on technology sensing and business development; Member of the **Leadership Team at BD Technologies**, Research Triangle Park, N.C.; Member of the Steering Committee for development of TB diagnostics; Member of the Steering Committee for Healthcare-Associated Infections; Marketing support including formation and direction of external expert advisory boards and presentation of national and international lectures; member of the Corporate Contributions Committee; responsibility for promoting external academic and professional relationships.

DIRECTORSHIPS:

ASM Resources, Inc (for-profit subsidiary of the American Society for Microbiology), 1999 - 2005 ;
Chairman of the Board, 2000 - 2005
BD Ventures Board, 2000 - 2007

Joint Commission Resources/Joint Commission International (subsidiary of The Joint Commission), 2002 – 2009; Chairman, Nominating Committee, 2006 – 2009; Member, Firewall Committee, 2005 – 2009; Finance Committee, 2008 – 2009
PixelEXX Systems Inc., 2013 -

BOARD OF TRUSTEES: National Foundation for Infectious Diseases, 1996 – 2005

US PATENT: Patent no. 9408984, “Self-injection device” issued 8/9/2016

OTHER INTERESTS: Private Pilot, Multi-engine, Instrument Rated,
3,125 hours Pilot in Command

BIBLIOGRAPHY PART 1: PRIMARY ARTICLES IN REFEREED JOURNALS

1. **Durack DT**, Gubbay SS, Kakulas BA: Electrophysiological studies in the Rottneest quokka with nutritional myopathy. *Aust J Exp Biol Med Sci* 47:581-588, 1969.
2. Kakulas BA, Owen CA, Papadimitriou JMM, **Durack DT**: The myocardial lesions in the Rottneest quokka with nutritional myopathy. *Proc Aust Assoc Neurol* 5:565-571, 1968.
3. **Durack DT**, Beeson PB: Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. *Br J Exp Path* 53:44-49, 1972.
4. **Durack DT**, Beeson PB: Experimental bacterial endocarditis. II. Survival of bacteria in endocardial vegetations. *Br J Exp Path* 53:50-53, 1972.
5. **Durack DT**, Petersdorf RG, Beeson PB: Penicillin prophylaxis of experimental *S. viridans* endocarditis. *Trans Assoc Am Phys* 85:222-230, 1972.
6. **Durack DT**: Experimental endocarditis. Doctoral Thesis, Bodleian Library, Oxford University, Oxford, England, 1972.
7. **Durack DT**, Beeson PB, Petersdorf RG: Experimental bacterial endocarditis. III. Production and progress of the disease in rabbits. *Br J Exp Path* 54:142-151, 1973.
8. **Durack DT**, Petersdorf RG: Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens. *J Clin Invest* 52:592-598, 1973.
9. **Durack DT**, Pelletier LL, Petersdorf RG: Chemotherapy of experimental streptococcal endocarditis. II. Synergism between penicillin and streptomycin against penicillin-sensitive streptococci. *J Clin Invest* 53:829-833, 1974.
10. Southwick FS, **Durack DT**: Chemotherapy of experimental streptococcal endocarditis. III. Failure of a bacteriostatic agent (tetracycline) in prophylaxis. *J Clin Path* 27:261-264, 1974.
11. **Durack DT**: Experimental bacterial endocarditis. IV. Structure and evolution of very early lesions. *J Path* 115:81-89, 1975.

12. **Durack DT**: Current practice in prevention of bacterial endocarditis. *Br Heart J* 37:478-481, 1975.
13. Pelletier LL, **Durack DT**, Petersdorf RG: Chemotherapy of experimental streptococcal endocarditis. IV. Further observations on antimicrobial prophylaxis. *J Clin Invest* 6:319-330, 1975.
14. **Durack DT**, Beeson PB: Protective role of complement in experimental *E. coli* endocarditis. *Infect Immun* 16:213-217, 1977.
15. **Durack DT**, Starkebaum MK, Petersdorf RG: Chemotherapy of experimental streptococcal endocarditis. VI. Prevention of enterococcal endocarditis. *J Lab Clin Med* 90:171-179, 1977.
16. Klebanoff SJ, **Durack DT**, Rosen H, Clark RA: Functional studies on human peritoneal eosinophils. *Infect Immun* 17:167-173, 1977.
17. Starkebaum MK, **Durack DT**, Beeson PB: The "incubation period" of subacute bacterial endocarditis. *Yale J Biol Med* 50:40-58, 1977.
18. Petersdorf RG, Pelletier LL, **Durack DT**: Some observations on experimental endocarditis. *Yale J Biol Med* 50:67-75, 1977.
19. Smith CK, **Durack DT**: Isoniazid and reaction to cheese. *Ann Intern Med* 88:520-521, 1978.
20. **Durack DT**, Gilliland BC, Petersdorf RG: Effect of immunization on susceptibility to experimental *Streptococcus mutans* and *Streptococcus sanguis* endocarditis. *Infect Immun* 21:52-56, 1978.
21. Goldman P, **Durack DT**, Petersdorf RG: Effect of antibiotics on prevention of experimental *Bacteroides fragilis* endocarditis. *Antimicrob Agents Chemother* 14:755-776, 1978.
22. **Durack DT**: The weight of medical knowledge. *New Engl J Med* 298:773-776, 1978.
23. **Durack DT**, Sumi SM, Klebanoff SJ: Neurotoxicity of human eosinophils. *Proc Nat Acad Sci* 76:1442-1447, 1979.
24. Snyderman R, **Durack DT**, McCarty GA, Ward FE, et al: Deficiency of the fifth component of complement in humans: Clinical, genetic and immunological studies in a large kindred. *Am J Med* 67:638-644, 1979.
25. Perfect JR, Lang SDR, **Durack DT**: Comparison of cotrimoxazole, ampicillin and chloramphenicol in treatment of experimental *Haemophilus influenzae* type b meningitis. *Antimicrob Agents Chemother* 17:43-48, 1980.
26. Lang SDR, Edwards DJ, **Durack DT**: Comparison of cefoperazone, cefotaxime and moxalactam (LY 127935) against aerobic gram-negative bacilli. *Antimicrob Agents Chemother* 17:488-493, 1980.
27. Perfect JR, Lang SDR, **Durack DT**: Chronic cryptococcal meningitis: A new experimental model in rabbits. *Am J Path* 101:177-194, 1980.

28. Lang SDR, **Durack DT**: *In vitro* efficacy of cefoperazone compared with cefotaxime, LY127935, and thienamycin. *Clin Therapeutics* 3:112-116, 1980
29. Perfect JR, **Durack DT**: Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulfamethoxazole in CSF of rabbits. *J Antimicrob Chemother* 8:49-58, 1981.
30. Washburn RG, **Durack DT**: Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental *Staphylococcus aureus* endocarditis. *J Infect Dis* 144:237-243, 1981.
31. **Durack DT**, Ackerman SJ, Loegering DA, Gleich GJ: Purification of human eosinophil-derived neurotoxin. *Proc Nat Acad Sci* 78:5165-5169, 1981.
32. Perfect JR, Lang SDR, **Durack DT**: Influence of agglutinating antibody in experimental cryptococcal meningitis. *Br J Exp Path* 62:595-599, 1981.
33. **Durack DT** and Perfect JR: Potential value of cefoperazone in bacterial meningitis: experimental studies. *Drugs* 22 (Suppl 1):60-64, 1981.
34. **Durack DT**, Corey GR, Perfect JR: Cotrimoxazole versus ampicillin in treatment of experimental *Streptococcus pneumoniae* meningitis. *Rev Infect Dis* 4(2):311-314, 1982.
35. Smego RA Jr, **Durack DT**: The neuroleptic malignant syndrome. *Archs Intern Med* 142:1183-1185, 1982.
36. **Durack DT**, Spanos A: End-of-treatment spinal tap in bacterial meningitis. Is it worthwhile? *J Am Med Assoc* 248:75-78, 1982.
37. Perfect JR, **Durack DT**: Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine and ketoconazole. *J Infect Dis* 146:429-435, 1982.
38. Meyers JD, Wade JC, Mitchell CD, Saral R, Lietman PS, **Durack DT**, Levin MJ, Segreti AC, Balfour HH Jr: Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. *Am J Med* 73 (Suppl.):229-235, 1982.
39. Perfect JR, **Durack DT**, Hamilton JD, Gallis HA: Failure of ketoconazole in cryptococcal meningitis. *J Am Med Assoc* 247:3349-3351, 1982.
40. Auckenthaler R, Wilson WR, Wright AJ, Washington JA, **Durack DT**, Geraci JE: Lack of *in vivo* and *in vitro* bactericidal activity of N-formimidoyl thienamycin against enterococci. *Antimicrob Agents Chemother* 22:448-452, 1982.
41. Cohen J, Perfect JR, **Durack DT**: Method for the purification of *Filobasidiella neoformans* basidiospores by flow cytometry. *Sabouraudia* 20:245-249, 1982.
42. Curiel TJ, Perfect JR, **Durack DT**: Leukocyte subpopulations in cerebrospinal fluid of normal rabbits. *Lab Animal Sci* 32:622-624, 1982.

43. Washburn DE, Perfect JR, **Durack DT**: Pharmacokinetics of N-formimidoyl thienamycin and influence of a renal dipeptidase inhibitor in experimental meningitis. *J Antimicrob Chemother* 12:39-45, 1983.
44. Brennan RO, **Durack DT**: Therapeutic significance of penicillin tolerance in experimental treptococcal endocarditis. *Antimicrob Agents Chemother* 23:273-277, 1983.
45. Brennan RO, Crain B, Proctor A, **Durack DT**: Cunninghamella: a newly recognized cause of rhinocerebral mucormycosis. *Am J Clin Path* 80:98-102, 1983.
46. Perfect JR, **Durack DT**, Gallis HA: Cryptococchemia. *Medicine* 62:98-109, 1983.
47. Hess J, Dankert J, **Durack DT**: Significance of penicillin tolerance in endocarditis. *J Antimicrob Chemother* 11:585-564, 1983.
48. **Durack DT**, Kaplan EL, Bisno AL: Apparent failures of endocarditis prophylaxis: Analysis of 52 cases submitted to a national registry. *J Am Med Assoc* 250:2318-2322, 1983.
49. McDonald MI, Hamilton JD, **Durack DT**: Hypothesis: Hepatitis B surface antigen could harbour the infective agent of AIDS. *Lancet* 2:882-884, 1983.
50. Smego RA Jr, **Durack DT**: An experimental model for *Naegleria fowleri* primary amoebic meningoencephalitis in rabbits. *J Parasitol* 70:78-81, 1984.
51. Smego RA Jr, **Durack DT**: *In vitro* susceptibility testing of *Naegleria fowleri* to ketoconazole, Bay N 7133, and allopurinol riboside. *J Parasitol* 70:317-318, 1984.
52. Smego RA, Perfect JR, **Durack DT**: Combined therapy with Amphotericin B and 5-Fluorocytosine for *Candida meningitis*. *Rev Infect Dis* 6:791-801, 1984.
53. McDonald MI, Corey GR, Gallis HA, **Durack DT**: Single and multiple pyogenic liver abscesses. Natural history, diagnosis and treatment, with emphasis on percutaneous drainage. *Medicine* 63:291-302, 1984.
54. McDonald M, Lucore C, **Durack DT**: An experimental model for pyogenic liver abscess. *J Infection* 8:129-136, 1984.
55. Thompson WM, Stude RA, McDonald MI, Halvorsen RA, Dunnick NR, Silverman PM, Korobkin M, **Durack DT**, Shelburne J: Computed tomographic evaluation of an experimental model for pyogenic liver abscesses. *Investigative Radiol* 20:152-158, 1985.
56. **Durack DT**: Current issues in prevention of infective endocarditis. *Am J Med* 78:149-156, 1985.
57. Granger DL, Perfect JR and **Durack DT**: Virulence of *Cryptococcus neoformans*: Regulation of capsule synthesis by carbon dioxide. *J Clin Invest* 76:508-516, 1985.
58. Perfect JR, **Durack DT**: Chemotactic activity of cerebrospinal fluid in experimental cryptococcal meningitis. *Sabouraudia: J Med Vet Mycology* 23:37-45, 1985.

59. Perfect JR, **Durack DT**: Effects of cyclosporine in experimental cryptococcal meningitis. *Infect Immun* 50:22-26, 1985.
60. Perfect JR, **Durack DT**: Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. *J Antimicrobial Chemother* 16:81-86, 1985.
61. Perfect JR, **Durack DT**: Comparison of amphotericin B and N-D-Ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and *Candida albicans* endocarditis with pyelonephritis. *Antimicrob Agents Chemother* 28:751-755, 1985.
62. Seaworth BJ, **Durack DT**: Infective endocarditis in obstetric and gynecologic practice. *Am J Obstet Gynec* 154:180-188, 1986.
63. Granger DL, Perfect JR, **Durack DT**: Macrophage-mediated fungistasis: requirement for a macromolecular component in serum. *J Immunol* 137:693-701, 1986.
64. Perfect JR, Savani DV, **Durack DT**: Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. *Antimicrobial Agents Chemother* 29:579-583, 1986.
65. Lucore CL, McDonald MI, Wharton M, **Durack DT**: Experimental anaerobic liver abscess: observations on treatment. *Liver* 6:214-132, 1986.
66. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, **Durack DT**: Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication to patients with AIDS or AIDS related complex. *Lancet*, 1:575-580, 1986.
67. Lallinger GJ, Reiner SL, Cooke DW, Toffaletti DL, Perfect JR, Granger DL, **Durack DT**: Efficacy of immune therapy in early experimental *Naegleria fowleri* meningitis. *Infect Immun* 55:1289-1293, 1987.
68. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, **Durack DT**, King D and the AZT Collaborative Working Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double-blind, placebo-controlled trial. *New Engl J Med* 317: 185-191, 1987.
69. Richmond DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, **Durack DT**, Nusinoff-Lehrman S, and the AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. A double-blind, placebo-controlled trial. *New Engl J Med* 317:192-197, 1987.
70. Cooke D, Lallinger G, **Durack D**: In vitro sensitivity of *Naegleria fowleri* to qinghaosu and dihydroqinghaosu. *J Parasitol* 73(2):411-413, 1987.
71. Savani DV, Perfect JR, Cobo LM, **Durack DT**: Penetration of new azole compounds into the eye and efficacy in experimental *Candida* endophthalmitis. *Antimicrob Agents Chemother* 31(1):6-10, 1987.

72. Perfect JR, Granger DL, **Durack DT**. Effects of antifungal agents and gamma-interferon on macrophage cytotoxicity for fungi and tumor cells. *J Infect Dis* 156:316-323, 1987.
73. Granger DL, Hibbs JB, Perfect JR, **Durack DT**: Specific amino acid (L-arginine) requirement for the microbistatic activity of murine macrophages. *J Clin Invest* 81:1129-1136, 1988.
74. Perfect JR, Hobbs MM, Granger DL, **Durack DT**: Cerebrospinal fluid macrophage cytotoxicity: *In vitro* and *in vivo* correlation. *Infect Immun* 56:849, 1988.
75. Hobbs MM, Perfect JR, **Durack DT**. Evaluation of the *in vitro* antifungal activity of LY121019. *Eur J Clin Microbiol* 7:77-80, 1988.
76. Kim J, **Durack D**. Manifestations of human T-lymphotrophic virus type I infection. *Am J Med* 84:919-928, 1988.
77. Weinhold KJ, Matthews TJ, Ahearne PM, Langlois AJ, Lyerly HK, Tyler DS, Stine KC, **Durack DT**, Bolognesi DP. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. *Lancet* 1:902-905, 1988.
78. Peacock JE, Jr, Kaplowitz LG, Sparling PF, **Durack DT**, Gnann JW, Jr, Whitley RJ, Lovett M, Bryson YJ, Klein RJ, Friedman-Kien AE, Knowlton GM, Davis LG. Intravenous acyclovir therapy of first episodes of genital herpes: A multicenter double-blind, placebo-controlled trial. *Am J Med*, 85:301-306, 1988.
79. Bisno AL, Dismukes WE, **Durack DT**, Kaplan EL, Karchmer AW, Kaye D, Rahimtoola SH, Sande MA, Sanford JP, Watanakunakorn C, Wilson WR. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. *J Am Med Assoc* 61:1471-1477, 1989.
80. Perfect JR, Wright KA, Hobbs MM, **Durack DT**: Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH 39304. *Antimicrob Agents Chemother* 33:1735-1740, 1989.
81. Perfect JR, Hobbs MM, Wright KA, **Durack DT**: Treatment of experimental disseminated candidiasis with cilofungin. *Antimicrob Agents Chemother* 33:1811-1812, 1989.
82. Spanos, A, Harrell FE, **Durack DT**: Differential diagnosis of acute meningitis. An analysis of the predictive value of initial observations. *J Am Med Assoc* 262:2700-2707, 1989. Also reprinted in *J Am Med Assoc (Indian edition)* 1990, and in *J Am Med Assoc (Pakistan edition)* 1:608-15, 1990. Also translated in *J Am Med Assoc (Italian edition)* 2:399-409, 1990.
83. Fischl MM, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, Laskin OL, Groopman JE, Volberding PA, Schooley RT, Jackson GG, **Durack DT**, Andrews JC, Nusinoff-Lehrman S, Barry DW and the AZT Collaborative Working Group: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. *J Am Med Assoc* 262:2405-2410, 1989.
84. Kaplan PW, Waterbury L, Kawas C, Bolla-Wilson K, **Durack D**: Reversible dementia with idiopathic hypereosinophilic syndrome. *Neurology* 39:1388-1391, 1989.

85. Granger DL, Hibbs JB, Perfect JR, **Durack DT**: Metabolic fate of L-arginine in relation to microbistatic capability of murine macrophages. *J Clin Invest* 85:264-273, 1990.
86. Hobbs MM, Perfect JR, Granger DL, **Durack DT**: Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. *Infect Immun* 58:2115-2119, 1990.
87. Dajani AS, Bisno AL, Chung KJ, **Durack DT**, Freed M, Gerber MA, Karchmer AW, Millard HD, Rahimtoola S, Shulman ST, Watanakunakorn C, Taubert KA: Prevention of bacterial endocarditis. Recommendations by the American Heart Association. *J Am Med Assoc* 264:2919-2922, 1990.
88. Lasky JA, Pulkingham N, Powers MA, **Durack DT**: *Rhodococcus equi* causing human pulmonary infection: review of 29 cases. *South Med J* 84:1217-1220, 1991.
89. Toffaletti DL, Rude TH, Johnston SA, **Durack DT**, Perfect JR. Gene transfer in *Cryptococcus neoformans* by use of biolistic delivery of DNA. *J Bacteriol* 175:1405-1411, 1993.
90. Cegielski JP, Msengi AE, Dukes CS, Mbise R, Redding-Lallinger R, Minjas JN, Wilson ML, Shao J, **Durack DT**. Intestinal parasites and HIV infection in Tanzanian children with chronic diarrhea. *AIDS* 7:213-221, 1993.
91. Ingram CW, Tanner DC, **Durack DT**, Kernodle GW, Jr, Corey GR. Disseminated infection with rapidly growing mycobacteria. *Clin Inf Dis* 16:463-471, 1993.
92. Perfect JR, Savani DV, **Durack DT**. Uptake of itraconazole by alveolar macrophages. *Antimicrob Agents Chemother.* 37:903-904, 1993.
93. Dajani AS, Ayoub E, Bierman FZ, Bisno AL, Denny FW, **Durack DT**, Ferrieri P, Freed M, Gerber M, Kaplan EL, Karchmer AW, Markowitz M, Rahimtoola SH, Shulman ST, Stollerman G, Takahashi M, Taranta A, Taubert KA, Wilson W. Guidelines for Diagnosis of Rheumatic Fever: Jones Criteria, Updated 1992. *Circulation* 87:302-307, 1993.
94. Dajani A, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, Takahashi M, Bierman FZ, Karchmer AW, Wilson W, Rahimtoola SH, **Durack DT**, Peter G. Diagnosis and therapy of Kawasaki disease in children. *Circulation*, 87:1776-1780, 1993.
95. Durack DT, Lukes AS, Bright DK, and the Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. *Am J Med* 96:200-209, 1994.
96. Heinle S, Wilderman N, Harrison JK, Waugh R, Bashore T, Nicely LM, **Durack D**, Kisslo J, and the Duke Endocarditis Service. Value of transthoracic echocardiography in predicting embolic events in active infective endocarditis. *Am J Cardiol* 74:799-801, 1994.
97. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, Bisno AL, Ferrieri P, Shulman ST, **Durack DT**. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. *J Am Med Assoc* 274:1706-1713, 1995.
98. **Durack DT**. Prevention of infective endocarditis. *N Engl J Med* 332:38-44, 1995.

99. Miller WC, Corey GR, Lallinger GJ, **Durack DT**: International health and internal medicine residency training: The Duke University Experience. *Am J Med* 99:291-297, 1995.
100. Johnson ES, Nicholson LG, **Durack DT**: Detection of antibodies to avian leukosis/sarcoma viruses (ALSV) and reticuloendotheliosis viruses (REV) in humans by ELISA. *Cancer Detection and Prevention* 19:394-404, 1995.
101. Dodds GA, III, **Durack DT**: Criteria for the diagnosis of endocarditis and the role of echocardiography. *Echocardiography* 12:663-668, 1995.
102. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, Dismukes W, Drew RH, **Durack DT**: Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. *Clin Infect Dis* 27:1470-4, 1998.
103. **Durack DT** and the Endocarditis Working Group of the International Society of Chemotherapy: Approach to the diagnosis of infective endocarditis. *Clin Microbiol Infect* 4:3S3-3S9, 1998.
104. Lockhart PB, **Durack DT**: Oral microflora as a cause of endocarditis and other distant site infections. *Infectious Dis Clin N America* 1999; 13:833-850, 1999.
105. Cabell CH, Pond KK, Peterson GE, **Durack DT**, Corey GR, Anderson DJ, Ryan T, Lukes AS, Sexton DJ. The risk of stroke and death in patients with aortic and mitral valve endocarditis. *American Heart Journal* 142(1):75-80, 2001.
106. Bishai D, Colchero A, **Durack DT**: The cost-effectiveness of antiretroviral treatment strategies in resource-limited settings. *AIDS* 21(10):1333-1340, 2007.
107. Wilson W, Taubert KA, Gewitz, M, et al., **Durack DT**: Prevention of Infective Endocarditis: Guidelines from the American Heart Association. *Circulation* 116:1736-54, 2007

BIBLIOGRAPHY PART 2: BOOK CHAPTERS, REVIEWS, EDITORIALS, LETTERS.

108. Tibbutt DA, **Durack DT**, MacFarlane JT, Teddy PJ: Bechet's syndrome and venous thrombosis. *Br Med J* 2:236, 1973.
109. **Durack DT**, Littler WA: Failure of "adequate" penicillin therapy to prevent bacterial endocarditis after tooth extraction. *Lancet* 2:846, 1974.
110. **Durack DT**: Chemoprophylaxis of bacterial endocarditis. *New Engl J Med* 292:1080, 1975.
111. **Durack DT**: Prevention of endocarditis: Dogma and debate. *Cardiology Today* 5:3, 1977.
112. **Durack DT**, Petersdorf RG: Changes in the epidemiology of endocarditis. In: *Infective Endocarditis--An American Heart Association Symposium*. Kaplan EL and Taranta AV (eds), American Heart Association Monograph No. 52, pp 3-8, 1977.

113. **Durack DT:** Experience with prophylaxis of experimental endocarditis. In: *Infective Endocarditis--An American Heart Association Symposium*, Kaplan EL and Taranta AV (eds), American Heart Association Monograph No. 52, pp 28-32, 1977.
114. Kaplan EL, Anthony BF, Bisno A, **Durack DT**, et al: Prevention of bacterial endocarditis. *Circulation* 56:139-143A, 1977.
115. **Durack DT:** Practical therapy of infective endocarditis. *Practical Cardiology* 3:77-81, 1977.
116. **Durack DT**, Beeson PB: Pathogenesis of infective endocarditis. In: *Infective Endocarditis*. Rahimtoola SH (ed), Grune and Stratton, New York, San Francisco, London, 1978, pp 1-53.
117. **Durack DT:** Pathogenesis and prevention of endocarditis. *Proceedings, VIIIth World Congress of Cardiology*, 1978.
118. Kaplan EL, **Durack DT:** *J Am Dent Assoc* 96:28-29, 1978.
119. What's new in endocarditis. *Cardiovascular Medicine* 4:545-551, 1979.
120. **Durack DT:** Infectious Diseases. In: *Review of General Internal Medicine*. LH Smith and JB Wyngaarden (eds), Saunders, Philadelphia, London, Toronto, 1980, pp 1-31.
121. Spanos A, **Durack DT:** New faces of infective endocarditis and how to recognize them. *J Cardiovasc Med* 1980:741-746
122. Brennan RO, **Durack DT:** Gay Compromise Syndrome. *Lancet* 2:1338, 1981.
123. Bisno AL, Dismukes WE, **Durack DT**, et al: Treatment of infective endocarditis due to viridans streptococci. *Circulation* 63:730A-733A, 1981.
124. **Durack DT:** Review of early experience in treatment of bacterial endocarditis, 1940-1955. In: *Treatment of Infective Endocarditis*. Bisno AL (ed), Grune and Stratton, 1981, pp 1-14.
125. Ackerman SJ, **Durack DT**, Gleich GJ: Eosinophil effector mechanisms in health and disease. In: *Advances in Host Defense Mechanisms*. Gallin JI and Fauci AS (eds), Raven Press, 1981, pp 269-293.
126. **Durack DT:** Infective and noninfective endocarditis. In: *The Heart*, 5th edition. Hurst JW (ed), McGraw-Hill and Co., New York, 1981. Also 6th edition, 1986. Also 7th edition, 1990, Ch 63, 1230-1255.
127. **Durack DT:** Opportunistic infections and Kaposi's sarcoma in homosexual men. *New Engl J Med* 305:1465-1467, 1981.
128. **Durack DT:** Infection in the immunocompromised host. In: *Clinical Aspects of Immunology*, 3rd edition. Lachmann P and Peters DK (eds), Blackwell, Oxford, London, Edinburgh, Melbourne, 1982, pp 1713-1751.
129. **Durack DT:** Pneumococcal pneumonia. In: *Cecil's Textbook of Medicine*, 16th edition. Wyngaarden JB and Smith LH (eds), Saunders, Philadelphia, London, Toronto, 1982, pp 1420-1427; 17th edition, 1985, pp 1498-1505; also 18th edition, 1988, pp 1554-1561.

130. Cohen J, Perfect JR, **Durack DT**: Cryptococcosis and basidiospores. *Lancet* 1:1301, 1982.
131. **Durack DT** and Perfect JR: Infections caused by *Haemophilus* species. In: *Internal Medicine*. Stein JH (ed), Little, Brown and Co., Boston, 1982, pp 1358-1362; also 2nd edition, 1987, pp 1675-1679; also 4th edition, 1994, Ch. 265, pp 2123-2128.
132. Brennan RO, **Durack DT**: Le Gay-syndrome. *J Internatl Med* 5:136-137, 1982.
133. **Durack DT** and Walker DH: Rickettsial infections. In: *Internal Medicine*. Stein JH (ed), Little, Brown and Co., Boston, 1982, pp 1315-1320; also 2nd edition, 1987, pp 1629-1634; also 4th edition, 1994, Ch 256, pp 2062-2068.
134. McDonald MI, **Durack DT**: Viral blisters. *Dermatologic Clinics of North America* 1:281-307, 1983.
135. **Durack DT**: The AIDS Epidemic. In: *Encyclopaedia Britannica Medical and Health Annual*, 1983, pp 24-37.
136. Cohen J, **Durack DT**: Infective Endocarditis. In: *Scientific Foundations of Cardiology*. Sleight P and Jones JR (eds), Wm. Heinemann Medical Books, Ltd, London, 1983, pp 305-313.
137. **Durack DT**: Infective endocarditis. In: *Infectious Diseases*, 3rd edition. Hoeprich PD (ed), Harper and Row, Philadelphia, 1983, pp 1171-1187; also 4th edition, 1989, pp 1237-1253; also 5th edition, 1994.
138. **Durack DT**: Current views on prevention. In: *Endocarditis*. Sande MA, Kaye D, Root RK (eds), Churchill Livingstone, New York, 1984, pp 213-225.
139. Brennan RO, **Durack DT**: The viridans streptococci in perspective. In: *Current Clinical Topics in Infectious Diseases*. Remington JS, Swartz MN (eds), McGraw-Hill, New York, 1984, pp 253-289.
140. **Durack DT**: The acquired immune deficiency syndrome. In: *Advances in Internal Medicine*, Volume 30. Stollerman GH et al (eds), Year Book Medical Publishers, Chicago, 1984, pp 29-51.
141. **Durack DT**: Prevention of central nervous system infections in patients at risk. *Am J Med* 76:231-237, 1984.
142. **Durack DT**: Nine controversies in the management of endocarditis. In: *Update V: Harrison's Principles of Internal Medicine*. Petersdorf RG et al (eds), McGraw-Hill, New York, 1984, pp 35-45.
143. **Durack DT**, Perfect JR: Acute bacterial meningitis. In: *Neurosurgery*. Wilkins RH (ed), 1985, pp 1921-1928.
144. **Durack DT**, Perfect JR: Experimental cryptococcal meningitis: a model for study of defense mechanisms in the central nervous system. In: *Bacterial Meningitis*. Sande MA, Kaye D, Root RK, (eds), Churchill Livingstone, New York, 1985, pp 71-82.

145. **Durack DT:** Infective endocarditis. In: *Cecil's Textbook of Medicine*, 17th edition. Wyngaarden JB, Smith LH (eds), Saunders, Philadelphia, 1985, pp 1533-1542; also 18th edition, pp 1586-1596; also 19th edition, 1991.
146. Sane DC, **Durack DT:** Infection with *Rhodococcus equi* in AIDS. *New Engl J Med* 314:56-57, 1986.
147. Cairns MR, **Durack DT:** Fungal pneumonia in the immunocompromised host. *Seminars in Respiratory Infections*, 1:166-185, 1986.
148. Tuomanen E, **Durack DT**, and Tomasz A: Minireview: Antibiotic tolerance among Clinical isolates of bacteria. *Antimicrob Agents Chemother* 30:521-527, 1986.
149. Ingram CW, **Durack DT.** How to evaluate pneumonia in immunocompromised patients: A systematic approach to diagnostic tests and treatment options. *J Critical Illness*, 3:71-85, 1988.
150. Perfect JR, **Durack DT:** Fungal meningitis. In: *Neurology and General Medicine*, Aminoff MJ (ed). Churchill-Livingstone, 1988, pp 625-641.
151. **Durack DT:** *Rus in Urbe*: Spotted fever comes to town. *New Eng J Med*, 318:21, 1388-1390, 1988.
152. **Durack DT:** The streptococci. In: *Mechanisms of Microbial Disease*. Schaechter M, Medoff G, and Schlessinger D (eds), Williams and Wilkins, Baltimore, 1989, pp 205-217.
153. **Durack DT:** *Pseudomonas aeruginosa*: A ubiquitous pathogen. In: *Mechanisms of Microbial Disease*. Schaechter M, Medoff G, and Schlessinger D (eds), Williams and Wilkins, Baltimore, 1989, pp 276-282.
154. Marrano NN, Mata LJ, **Durack DT:** Cutaneous leishmaniasis in rural Costa Rica. *Trans R Soc Trop Med Hyg* 83:340, 1989.
155. **Durack DT:** Blood and circulation. In: *Mechanisms of Microbial Disease*. Schaechter M, Medoff G, and Schlessinger D (eds), Williams and Wilkins, Baltimore, 1989, pp 710-722.
156. **Durack DT:** Fever of unknown origin. In: *Mechanisms of Microbial Disease*. Schaechter M, Medoff G, and Schlessinger D (eds), Williams and Wilkins, Baltimore, 1989, pp 765-770.
157. **Durack DT:** Infective Endocarditis. In: *The Heart Seventh Edition Companion Handbook*. Schlant R and Hurst J Willis (eds), McGraw Hill Inc, New York, 1990, Chapter 15, pp 153-167.
158. **Durack DT:** Prophylaxis of infective endocarditis. In: *Principles and Practice of Infectious Diseases*, Mandell GL, Douglas RG, Bennett JE (eds). Churchill Livingstone, New York, 1990, 3rd edition, Ch 63, pp 716-721. (Also 4th and 5th editions).
159. **Durack DT**, Street AS: Fever of unknown origin: Reexamined and redefined. In: *Current Clinical Topics in Infectious Diseases*. Remington JS and Swartz MN (eds), 1990, pp 35-51.

160. Dajani AS, Bisno AL, Chung KJ, **Durack DT**, Gerber MA, Kaplan EL, Millard HD, Randolph MF, Shulman ST, Taubert KA, Watanakunakorn C: Diagnostic guidelines for Kawasaki Disease. *Am J Dis Child* 144:1218-1219, 1990.
161. Tanner D and **Durack DT**: Infective endocarditis. *Current Opinion in Infectious Diseases* 3:643-652, 1990.
162. **Durack DT**, Whitley RJ, Scheld WM: Approach to the patient with central nervous system infection. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Raven Press, New York, 1991, Ch 1, pp 1-6.
163. Kim JH, **Durack DT**: Rickettsiae and the central nervous system. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Raven Press, New York, 1991, Ch 17, pp 411-424.
164. Perfect JR, **Durack DT**: Pathogenesis and pathophysiology of fungal infections of the central nervous system. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Raven Press, New York, 1991, Ch 29, pp 693-702.
165. Cegielski JP, **Durack DT**: Protozoal infections of the central nervous system. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Raven Press, New York, 1991, Ch 33, pp 767-800.
166. Dukes CS, Luft BJ, **Durack DT**: Toxoplasmosis of the central nervous system. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Raven Press, New York, 1991, Ch 34, pp 801-824.
167. Cameron ML, **Durack DT**: Helminthic infections of the central nervous system. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Raven Press, New York, 1991, Ch 35, pp 825-858.
168. **Durack D**. Use of third-generation cephalosporins. Streptococci. *Hospital Practice* 26 Suppl 4:6-10, 1991.
169. **Durack DT**. Fever of unknown origin. In *Mechanisms of Microbial Disease*. Schaechter M, Medoff G, Eisenstein BI (eds). 1993, Ch 70, pp 859-864.
170. **Durack DT**. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Endocarditis. *Hospital Practice* 28 Suppl 2:6-9, 1993.
171. **Durack DT**, Andriole VT, Hornick RB, Karchmer AW, Marier RL and Quie PG. Guidelines for Ethical Conduct by Members and Fellows of the Infectious Diseases Society of America. *J Infect Dis*, 167:257-258, 1993.
172. **Durack DT**, Karchmer AW, Blair R, Wilson W, Dismukes W, Tice A, Gilbert D, Tenenbaum M, Farber B, Tauber M. Home intravenous antibiotic therapy. *Am J Med*, 94:114, 1993.
173. Lukes A, **Durack DT**. Infective endocarditis. *Current Opinion in Cardiology* 8:502-510, 1993.

174. Kim JH, **Durack DT**. Ethical issues in infectious diseases. In: *Current Clinical Topics in Infectious Diseases*. Remington JS, Swartz MN (eds), Blackwell Scientific Publications, 1994, pp 266-275.
175. Miller WC, **Durack DT**. Fever of Unknown Origin: A rational diagnostic approach. *Hospital Medicine* 30:49-56, 1994.
176. Fowler VG, **Durack DT**: Infective endocarditis. *Current Opinion in Cardiology* 9:389-400, 1994.
177. Cox GM, Perfect JR, **Durack DT**: Fungal Infections and the Central Nervous System. In: *Neurology and General Medicine*, 2nd Edition, Aminoff MJ (ed). Churchill-Livingstone, 1994, Ch 40, pp 791-80x..
178. **Durack DT**. Fever of Unknown Origin. *Oxford Textbook of Medicine*, Eds Weatherall D, Ledingham JGG, Warrell DA. Third Edition, 1995.
179. **Durack DT**, Whitley RJ, Scheld WM: Approach to the patient with central nervous system infection. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 1, pp 1-6.
180. Kim JH, **Durack DT**: Rickettsiae. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 22, pp 403-416.
181. Perfect JR, **Durack DT**: Fungal meningitis In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 38, pp 721-740.
182. Dukes CS, Luft BJ, **Durack DT**: Toxoplasmosis. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 41, pp 785-806.
183. Cegielski JP, **Durack DT**: Trypanosomiasis. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 42, pp 807-830.
184. **Durack DT**: Amebic infections In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 43, pp 831-844.
185. Cameron ML, **Durack DT**: Helminthic infections. In: *Infections of the Central Nervous System*. Scheld WM, Whitley RJ, **Durack DT** (eds). Lippincott-Raven Publishers, Philadelphia, 1997, Ch 44, pp 845-880.
186. **Durack DT**: Fever of Unknown Origin. In: *Fever: Basic Mechanisms and Management*. Mackowiak PA (ed). Lippincott-Raven Publishers, Philadelphia. 1997, Ch 15, pp 237-249.
187. **Durack DT**, Towns ML: Diagnosis and Management of Infective Endocarditis. In: *Evidence Based Cardiology*. Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ (eds). BMJ Books, London. 1998, Ch 52, pp 804-904.

188. **Durack DT:** Infective endocarditis. In: *Hurst's The Heart*, 9th edition. Alexander RW, Schlant RC, Fuster V (eds), McGraw-Hill and Co., New York, 1998. Ch 82, pp 2205-2239.
189. **Durack DT:** Antibiotics for prevention of endocarditis during dentistry: Time to scale back? *Ann Intern Med* 1998; 129:829-831.
190. Armstrong D, Cohen J, (editors), **Durack DT**, Finch R, Ronald AR, et al (Section editors) "*Infectious Diseases*" Harcourt Brace Mosby, London, 1999.
191. Lockhart PB, **Durack DT:** Oral microflora as a cause of endocarditis and other distant site infections. *Infectious Diseases Clinics of North America* 1999; 13:833-850.
192. **Durack DT:** Endocarditis: Getting to the heart of the matter. Discovery Series: Turning points in Infectious Diseases, *Infectious Diseases in Clinical Practice*, Article #28, 7/2000.
193. **Durack DT:** Fever of Unknown Origin. In: *Concise Oxford Textbook of Medicine*, Ledingham JG, Warrell DA (eds) Oxford University Press, Oxford, 2000, Ch 16.115, pp 1821-1825.
194. **Durack DT:** Epidural abscess. *Up-To-Date*, 2000: Volume 8, No 3.
195. **Durack DT**, Littman RJ, Benitez RM, Mackowiak PA: Hellenic Holocaust: A Historical Clinico-Pathologic Conference. *Am J Med* 2000; 109:391-397.
196. Cox GM, Perfect JR, **Durack DT:** Fungal Infections and the Central Nervous System. In: *Neurology and General Medicine*, 3rd Edition, Aminoff MJ (editor). Churchill-Livingstone, 2001, Ch 40, pp 791-809.
197. **Durack DT** (ed): Infective Endocarditis (Preface). *Infectious Diseases Clinics of North America* 2002; 16: xv-xix.
198. Lepidi H, **Durack DT**, Raoult D: Diagnostic methods: Current best practices and guidelines for histologic evaluation of infective endocarditis. *Infectious Diseases Clinics of North America* 2002; 16: 339-362.
199. Lisby G, Gutschik E, **Durack DT:** Molecular methods for diagnosis of infective endocarditis. *Infectious Diseases Clinics of North America* 2002; 16: 255-533.
200. **Durack DT:** Endocarditis. *In Antibiotic and Chemotherapy*. Finch RG, Greenwood D, Norrby RS, Whitley RJ, (editors) 8th Edition, 2003. Ch 49, pp 657-666.
201. Crawford MH, **Durack DT:** Clinical presentation of infective endocarditis. *Cardiology Clinics* 2003; 21(2): 159-166.
202. **Durack DT:** Evaluating and optimizing results of surgery for endocarditis. *JAMA* 2003; 290:3250-3251.
203. Shahzad M, **David T. Durack DT**, Steele RW: Meningitis in a young infant. *Infect Med* 21(9):419-421, 2004.

204. **Durack DT**, Karchmer AW: 18 Infective Endocarditis. 7 Infectious Diseases. ACP Medicine Online. Dale DC, Federman DD, (editors). WebMD Inc., New York, 2004. <http://acpmedicine.com> December, 2004
205. **Durack DT**: Prophylaxis of infective endocarditis. In: *Principles and Practice of Infectious Diseases*, Mandell GL, Bennett JE, Dolin R (editors). Elsevier Churchill Livingstone, Philadelphia, 2005, 5th edition, Ch 76, pp 1044-1052.
206. **Durack DT**, Karchmer AW: Infective Endocarditis. In ACP Medicine, 2006 edition. Dale DC, Federman DD, (editors). WebMD Professional Publishing, New York, 2006, Ch132, pp 1488-1505.
207. Bishai D, Colchero A, **Durack DT**: The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 21:1333-40, 2007.
208. **Durack DT**: Prevention of infective endocarditis. In: *Principles and Practice of Infectious Diseases*, Mandell GL, Douglas RG, Bennett JE (eds). Churchill Livingstone, New York, 2010, 7th edition, Ch 80, pp 1143-1152.
209. **Durack DT**. Dunn JJ: Fostering partnerships between Industry and the Clinical Microbiology laboratory. J Clin Micro 49:S78-S79, 2011.
210. **Durack DT**: Prevention of infective endocarditis. In: Mandell, Douglas and Bennett's *Principles and Practice of Infectious Diseases*, Bennett JE, Dolin R, Blaser MJ, (eds). Elsevier, 8th edition, 2014

BIBLIOGRAPHY PART 3: ABSTRACTS

1. **Durack DT**, Petersdorf RG, Beeson PB: Penicillin prophylaxis of experimental endocarditis. Quart J Med 41:535, 1972.
2. **Durack DT**, Petersdorf RG, Beeson PB: Penicillin prophylaxis of experimental *S. viridans* endocarditis. Clin Res 20:630, 1972.
3. **Durack DT**, Petersdorf RG: Experimental *Streptococcus viridans* endocarditis: Alternatives to penicillin prophylaxis. J Clin Invest 51:25A, 1972.
4. Starkebaum MK, **Durack DT**: Prevention of experimental enterococcal endocarditis. Clin Res 24:152A, 1976.
5. **Durack DT**: Importance of the bactericidal effect of serum in pathogenesis of experimental *E. coli* endocarditis. Clin Res 24:343A, 1976.
6. **Durack DT**: Increased susceptibility of C6-deficient rabbits to *E. coli* endocarditis. 16th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract No. 65, 1976.
7. **Durack DT**, Petersdorf RG: Chemotherapy of experimental *B. fragilis* bacteremia. Clin Res 25:375A, 1977.

8. **Durack DT:** Role of complement in susceptibility to experimental *E. coli* meningitis. 17th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1977.
9. **Durack DT:** Neisseria infections in C6-deficient rabbits. Clin Res 26:394A, 1978.
10. Perfect JR, Lang SDR, **Durack DT:** Cryptococcosis in rabbits: A model for chronic meningitis. 19th Interscience Conference of Antimicrobial Agents and Chemotherapy, 1979.
11. Perfect JR, Lang SDR, **Durack DT:** Comparison of cotrimoxazole (TMP/SMX), ampicillin (AMP) and chloramphenicol (CHLORO) in treatment of experimental *Haemophilus influenzae* type B (HITB) meningitis. Clin Res 27:353A, 1979.
12. **Durack DT:** Relative influence of K1 antigen and resistance to complement lysis on pathogenesis of experimental *E. coli* meningitis. Clin Res:477A, 1979.
13. Crowley JP, **Durack DT** and Peter G: Core glycolipid antibody opsonization of *E. coli* and virulence. Clin Res 28:366A, 1980.
14. Perfect JR, Lang SDR and **Durack DT:** Influence of humoral immunity on cryptococcal meningitis in rabbits. Clin Res 28:376A, 1980.
15. Washburn RG, Edwards DE, Perfect JR and **Durack DT:** Ampicillin plus a B-lactamase-inhibitor is effective in experimental nafcillin-sensitive (S) and resistant (R) *Staph. aureus* endocarditis. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, 278, 1980.
16. Perfect JR, **Durack DT:** Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim, and sulfamethoxazole in CSF rabbits. 20th Interscience Conference on Antimicrobial Agents, 1980.
17. Perfect JR and **Durack DT:** Comparison of amphotericin (AMB), 5-Fluorocytosine (5FC) and ketoconazole (KTZ) in treatment of experimental cryptococcal meningitis. 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, 476, 1980.
18. Twenty-five cases of apparent endocarditis prophylaxis failure: Results of a national survey. Clin Res 29:384A, 1981.
19. Perfect JR, **Durack DT** and Gallis HA: Cryptococemia. Clin Res 29:393A, 1981.
20. Curiel TJ, Perfect JR and **Durack DT:** Cellular response in cerebrospinal fluid in experimental cryptococcal meningitis. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy. 1981.
21. Edwards DE, Perfect JR and **Durack DT:** Pharmacokinetics of N-formimidoyl thienamycin (MK0787) with and without a renal dehydropeptidase inhibitor (MKO791) in CSF of rabbits. 21st Interscience Conference on Antimicrobial Agents and Chemotherapy, 1981.
22. **Durack DT,** Perfect JR, Hess J and Kankert J: Tolerance in viridans streptococci exerts a major influence on efficacy of penicillin *in vivo*. Clin Res 30:364A, 1982.

23. McDonald MI and **Durack DT**: Complement-mediated serum bactericidal activity in neonates. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1982.
24. **Durack DT** and Toffaletti DL: A new method for measurement of complement-mediated serum bactericidal activity;. Clin Res 30:518A, 1982.
25. **Durack DT**, Bisno AL and Kaplan EL: Analysis of 52 cases of apparent failure of endocarditis prophylaxis. Circulation 65-66, Suppl. 2, 102, 1982.
26. Perfect JR, **Durack DT**, Gallis HA: Cryptococemia. 2nd International Symposium on Infections in the Immunocompromised Host, 1982.
27. Perfect JR, Washburn DE, **Durack DT**: Chemotactic activity in CSF from rabbits with experimental cryptococcal meningitis. 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1982.
28. McDonald MI, Lucore CL, **Durack DT**: An experimental model for pyogenic liver abscess. Am Soc Microbiol, 83rd Ann Meeting, 1983.
29. McDonald MI, Lucore CL, **Durack DT**: Experimental aspects of pyogenic liver abscess. Australian Society for Infectious Diseases, 1983.
30. Washburn DE, Perfect JR, Dankert J, **Durack DT**: Tolerance of *Streptococcus sanguis* to N-formimidoyl thienamycin (MKO787) and penicillin G. Am Soc Micro, 83rd Ann Meeting.
31. Perfect JR, **Durack DT**: Serum and CSF pharmacokinetics of BAYn7133 related to *in vitro* and *in vivo* activity. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1983.
32. Perfect JR, Washburn DE, **Durack DT**: Amphotericin B (AMB) and n-ornithyl amphotericin B methyl ester (O-AME) in treatment of experimental cryptococcal meningitis. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1983.
33. Perfect JR, Washburn DE, **Durack DT**: Amphotericin B (AMB) and n-ornithyl amphotericin B methyl ester (O-AME) in treatment of experimental cryptococcal meningitis. Clin Res, 1983.
34. Granger DL, Perfect JR, and **Durack DT**: Carbon dioxide regulates capsule production by *Cryptococcus neoformans*. Clin Res, 369A, 1984.
35. Perfect JR, Gross M, Pickard W, and **Durack DT**: Amphotericin B (AMB) usage at Duke Hospital in 1983. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984.
36. Perfect JR and **Durack DT**: The antifungal activity of R51211 in treatment of experimental candida pyelonephritis and cryptococcal meningitis. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984.
37. Perfect JR, Granger DL and **Durack DT**: Effect of antifungal agents on macrophage activation. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984.

38. Granger DL, Perfect JR and **Durack DT**: Macrophage fungistasis: Requirements for inhibition of *Cryptococcus neoformans*. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984.
39. Perfect JR, Granger DL and **Durack DT**: Cyclosporine predisposes to experimental cryptococcal meningitis. Clin Res, 379A, 1984.
40. Savani DV, Perfect JR, Cobo LM and **Durack DT**: Penetration of ocular tissue and fluids by azoles in rabbits. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1985.
41. Perfect JR, Granger DL and **Durack DT**: Macrophage fungistasis and fungicidal activity: Interaction with immune modulators and antifungal agents. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1985.
42. Reiner SL, Lallinger GJ, Perfect JR, Granger DL and **Durack DT**: Combined amphotericin B and Immunotherapy for experimental amebic meningoencephalitis. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1985.
43. Lallinger GJ, Reiner SL, Perfect JR and **Durack DT**: Serum therapy of experimental *Naegleria fowleri* meningitis. Clin Res, 408A, 1985.
44. Granger DL, Perfect JR and **Durack DT**: Macrophages require a serum factor(s) for efficient fungistasis. Clin Res, 565A, 1985.
45. Good SS, **Durack DT**, de Miranda P: Biotransformation in various species and in humans of 3'-azido-3'-deoxythymidine, a potential agent for the treatment of AIDS. FASEB Abstracts, April, 1986.
46. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, **Durack DT**: Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS related complex. Clin Res, 511A, 1986.
47. Wharton M, Granger DL, **Durack DT**: Mitochondrial iron loss in L1210 leukemia cells injured by activated macrophages: a possible mechanism for electron transport chain defects. Clin Res, 571A, 1986.
48. Granger DL, Perfect JR, **Durack DT**: Role of iron and heme binding serum proteins in macrophage fungistasis. Clin Res, 658A, 1986.
49. Perfect JR, Hobbs MM, Granger DL, **Durack DT**: Dynamics of cerebrospinal fluid macrophage activation in experimental cryptococcal meningitis. Clin Res, 678A, 1986.
50. Dankert J, Hess J, **Durack D**: Pathogenesis of Viridans Streptococcal Endocarditis (VSE): Disappearance of adherent streptococci from vegetations. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986.
51. Hobbs MM, Perfect JR, Granger DL and **Durack DT**: Opsonic Activity of Cerebrospinal Fluid in Experimental Cryptococcal Meningitis. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986.

52. Cook DW, Toffaletti DL, Lallinger GL and **Durack DT**: Monoclonal antibody to *Naegleria fowleri* in treatment of experimental amebic meningoencephalitis. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986.
53. Savani D, Perfect JR and **Durack DT**: Activity of anti-cancer drugs against yeasts *in vitro*. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986.
54. Perfect JR, Penning LM, Granger DL and **Durack DT**: Factors influencing the uptake of *Mycobacterium avium-intracellulare* (MAI) by alveolar macrophages (AMO). 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986.
55. Granger DL, Hibbs JR, Perfect JR, **Durack DT**. Arginine-dependent microbiostatic pathway of macrophages producing NO₂⁻/NO₃⁻ Clin Res, 615A, 1987.
56. Savani DV, Perfect JR, **Durack DT**. Comparison of LY146032, ampicillin plus gentamicin and vancomycin in the treatment of Enterococcal pyelonephritis and endocarditis in rabbits. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987.
57. Granger DL, Hibbs JB, Perfect JR, **Durack DT**. Macrophage fungistasis is coupled to a unique pathway of L-arginine metabolism. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987.
58. Hobbs MM, Perfect JR, **Durack DT**. *In vitro* susceptibility of Candida species to LY121019 and amphotericin B. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987.
59. Savani DV, Perfect JR, **Durack DT**. Uptake of tritiated itraconazole by alveolar macrophages. Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, 1987.
60. Cooke D, Toffaletti D, Lallinger G, Durack D. A new technique for *in vitro* testing of anti-protozoal drugs. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988.
61. Hobbs MM, Wright KA, Perfect JR, Tso CY, **Durack DT**. Efficacy of SCH39304 and fluconazole in the treatment of experimental fungal infections. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988.
62. Hobbs MM, Wright KA, Perfect JR, Tso CY, **Durack DT**. Efficacy of LY121019 and amphotericin B in disseminated candidiasis in rabbits. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988.
63. Granger DL, Penning L, Ross DO, Broadnax LM, **Durack DT**. Murine Cryptococcosis: Deficient *in vitro* nitrite synthesis by peritoneal macrophages. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988.
64. Granger DL, Hibbs, JB, Perfect JR, **Durack DT**: Macrophage fungistasis is coupled to a unique pathway of L-arginine metabolism. J Clin Invest, 1988.

65. Toffaletti DL, Penning LM, **Durack DT**. Susceptibility of *Naegleria fowleri* to peptide toxins. Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989.
66. Fracica LA, George LA, **Durack DT**. Routine antigen screening of specimens sent for HIV serology is not cost-effective. Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989.
67. Marrano NN, Granger DL, Ross DO, **Durack DT**. Role of L-arginine oxidation pathway in toxoplasmosis by murine peritoneal macrophages. Twenty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989.
68. Cegielski JP, Dukes CS, **Durack DT**, Mbise R, Minjas JN, Msengi AE, Redding-Lallinger R, Shao J. Intestinal parasites associated with HIV infection in children with chronic diarrhea in Dar es Salaam, Tanzania. Abstract, Vth International Conference on AIDS in Africa, Kinshasa, Zaire, 1990.
69. Kim SA, **Durack DT**, Bashore TM, Waugh RA, Kisslo J and the Duke Endocarditis Service. Can the echocardiographer effectively predict the risk of embolization during infective endocarditis? American Heart Association 64th Scientific Sessions, Anaheim CA, November 11-14, 1991.
70. **Durack DT** and The Duke Endocarditis Service: Natural history and prognosis of infective endocarditis in the 1990's: implications for therapy. Abstract No. 199, p 38, 5th European Congress of Clinical Microbiology and Infectious Diseases, Oslo, Norway, September 9-11, 1991.
71. Kim S, **Durack D**, Bashore T, Waugh R, Nicely M, Harrison K, Kisslo J and Duke University Endocarditis Service. The clinical utility of transesophageal echocardiography in management of patients with suspected infective endocarditis. American College of Cardiology, Dallas, Texas, April 12-16, 1992.
72. Lallinger G, Komba M, **Durack D**, Mahikwano L, Minjas J. Health survey of a rural cohort in Tanzania. International Congress for Infectious Diseases, Nairobi, Kenya, June 7-11, 1992.
73. Lallinger G, Miller W, **Durack D**, Thielman N, Beiser C, Cegielski P, Shao J. Treatment of diarrhea with ciprofloxacin in HIV infected patients in Tanzania. International Congress for Infectious Diseases, Nairobi, Kenya, June 7-11, 1992.
74. Tice FD, Heinle SK, Lukes AS, Nicely LM, **Durack DT**, Kisslo J, Duke Endocarditis Service. Are serial echocardiograms useful in patients with infective endocarditis? American Heart Association, November 8-11, 1993.
75. Kacena, KA, Moore R, O'Keefe C, Quinn TC, Apfalter P, **Durack DT**, Gaydos CA. Detection of *Chlamydia pneumoniae* by real-time strand displacement. 4th European Chlamydia Congress, Helsinki, 8/2000.
76. Bishai D, Colchero MA, **Durack DT**: Cost effectiveness of CD4 laboratory monitoring in HAART. Abstract no. WePeLB11.5C02, 3rd International AIDS Society, Rio de Janeiro, 7/2005

